Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Director Bernhardt G. Zeiher Acquires 10,000 Shares

Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Director Bernhardt G. Zeiher bought 10,000 shares of the business’s stock in a transaction on Thursday, March 20th. The stock was bought at an average price of $3.70 per share, for a total transaction of $37,000.00. Following the transaction, the director now directly owns 10,000 shares of the company’s stock, valued at approximately $37,000. This represents a ∞ increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which is available at the SEC website.

Amylyx Pharmaceuticals Price Performance

Shares of AMLX stock opened at $3.81 on Thursday. Amylyx Pharmaceuticals, Inc. has a one year low of $1.58 and a one year high of $7.27. The business’s 50 day simple moving average is $3.54 and its 200 day simple moving average is $4.01. The stock has a market capitalization of $337.57 million, a PE ratio of -1.00 and a beta of -0.51.

Amylyx Pharmaceuticals (NASDAQ:AMLX) last posted its quarterly earnings data on Tuesday, March 4th. The company reported ($0.55) earnings per share for the quarter, missing the consensus estimate of ($0.49) by ($0.06). The firm had revenue of ($0.67) million for the quarter. As a group, research analysts expect that Amylyx Pharmaceuticals, Inc. will post -2.2 earnings per share for the current year.

Institutional Investors Weigh In On Amylyx Pharmaceuticals

Several large investors have recently added to or reduced their stakes in AMLX. Blue Trust Inc. lifted its stake in Amylyx Pharmaceuticals by 232.1% in the fourth quarter. Blue Trust Inc. now owns 6,987 shares of the company’s stock valued at $26,000 after buying an additional 4,883 shares during the period. XTX Topco Ltd lifted its position in shares of Amylyx Pharmaceuticals by 12.0% during the 4th quarter. XTX Topco Ltd now owns 53,376 shares of the company’s stock valued at $202,000 after acquiring an additional 5,704 shares during the period. Northern Trust Corp lifted its position in shares of Amylyx Pharmaceuticals by 11.8% during the 4th quarter. Northern Trust Corp now owns 106,564 shares of the company’s stock valued at $403,000 after acquiring an additional 11,214 shares during the period. Fox Run Management L.L.C. bought a new position in Amylyx Pharmaceuticals during the fourth quarter worth $45,000. Finally, Alpine Global Management LLC acquired a new stake in Amylyx Pharmaceuticals in the fourth quarter worth $45,000. Institutional investors and hedge funds own 95.84% of the company’s stock.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reissued a “buy” rating and set a $12.00 price objective on shares of Amylyx Pharmaceuticals in a report on Wednesday, March 5th. Three investment analysts have rated the stock with a hold rating, three have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Amylyx Pharmaceuticals has a consensus rating of “Moderate Buy” and an average target price of $7.33.

Amylyx Pharmaceuticals Company Profile

Amylyx Pharmaceuticals, Inc, a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada.